Edge Therapeutics Inc (NASDAQ:EDGE) CEO Brian A. Leuthner sold 2,500 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $10.81, for a total value of $27,025.00. Following the completion of the sale, the chief executive officer now directly owns 110,236 shares of the company’s stock, valued at approximately $1,191,651.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Edge Therapeutics Inc (NASDAQ:EDGE) traded up 0.72% during midday trading on Wednesday, reaching $11.16. The company’s stock had a trading volume of 23,033 shares. The stock’s 50-day moving average price is $10.20 and its 200-day moving average price is $9.97. Edge Therapeutics Inc has a 12-month low of $7.30 and a 12-month high of $13.50. The company’s market cap is $344.30 million.

Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). On average, analysts expect that Edge Therapeutics Inc will post ($1.87) EPS for the current fiscal year.

WARNING: “Edge Therapeutics Inc (EDGE) CEO Brian A. Leuthner Sells 2,500 Shares” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/04/edge-therapeutics-inc-edge-ceo-brian-a-leuthner-sells-2500-shares.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in shares of Edge Therapeutics by 1.7% in the 1st quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 200 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Edge Therapeutics by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 75,279 shares of the biotechnology company’s stock valued at $773,000 after acquiring an additional 532 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Edge Therapeutics by 2.1% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 48,000 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 1,000 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Edge Therapeutics by 16.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,733 shares during the last quarter. Finally, Teachers Advisors LLC increased its holdings in shares of Edge Therapeutics by 8.2% in the 4th quarter. Teachers Advisors LLC now owns 28,353 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 2,150 shares during the last quarter. Institutional investors and hedge funds own 49.38% of the company’s stock.

Several equities research analysts have weighed in on the company. BidaskClub downgraded Edge Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Zacks Investment Research raised Edge Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Stock Ratings for Edge Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc and related stocks with our FREE daily email newsletter.